dx 8951 has been researched along with gemcitabine in 7 studies
Studies (dx 8951) | Trials (dx 8951) | Recent Studies (post-2010) (dx 8951) | Studies (gemcitabine) | Trials (gemcitabine) | Recent Studies (post-2010) (gemcitabine) |
---|---|---|---|---|---|
73 | 18 | 15 | 12,523 | 3,208 | 6,923 |
Protein | Taxonomy | dx 8951 (IC50) | gemcitabine (IC50) |
---|---|---|---|
Chain A, DEOXYNUCLEOSIDE KINASE | Drosophila melanogaster (fruit fly) | 0.76 | |
Equilibrative nucleoside transporter 1 | Homo sapiens (human) | 0.19 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 6 (85.71) | 29.6817 |
2010's | 1 (14.29) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Bouvet, M; Hoffman, RM; Moossa, AR; Nassirpour, R; Sun, FX; Tohgo, A; Yagi, S | 1 |
Richards, DA | 1 |
Chua, YJ; Cunningham, D | 1 |
Abou-Alfa, GK; Ackerman, J; De Jager, RL; Eckhardt, SG; Feit, K; Harker, G; Hurwitz, H; Letourneau, R; Modiano, M; O'Reilly, EM; Tchekmedyian, NS | 1 |
Owen, OG | 1 |
Li, XF; Liu, GF; Liu, L; Yu, SN; Zhang, SH | 1 |
3 review(s) available for dx 8951 and gemcitabine
Article | Year |
---|---|
Chemotherapeutic gemcitabine doublets in pancreatic carcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Survival Rate | 2005 |
Chemotherapy for advanced pancreatic cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Organoplatinum Compounds; Palliative Care; Pancreatic Neoplasms; Pemetrexed; Taxoids; Topoisomerase I Inhibitors | 2006 |
Efficacy of different chemotherapy regimens in treatment of advanced or metastatic pancreatic cancer: A network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Network Meta-Analysis; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2018 |
1 trial(s) available for dx 8951 and gemcitabine
Article | Year |
---|---|
Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2006 |
3 other study(ies) available for dx 8951 and gemcitabine
Article | Year |
---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Efficacy of camptothecin analog DX-8951f (Exatecan Mesylate) on human pancreatic cancer in an orthotopic metastatic model.
Topics: Animals; Camptothecin; Deoxycytidine; Disease Models, Animal; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasm Metastasis; Pancreatic Neoplasms; Tumor Cells, Cultured | 2003 |
Exatecan and gemcitabine: no better than gemcitabine only.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Survival Rate | 2006 |